In contrast, there are some drugs such as pioglitazone, which not only improve insulin sensitivity but also can retard preclinical atherogenesis in patients with T2DM, at least in part by a reduction in PAI-1 expression [25]. Here, INS is linked to type 2 diabetes mellitus.